Scarica l'app Stockscreener
14.22
6.26%
-0.95
Dopo l'orario di chiusura:
14.22
Precedente Chiudi:
$15.17
Aprire:
$14.91
Volume 24 ore:
3.32M
Relative Volume:
0.98
Capitalizzazione di mercato:
$1.97B
Reddito:
-
Utile/perdita netta:
$-191.97M
Rapporto P/E:
-4.5036
EPS:
-3.1575
Flusso di cassa netto:
$-159.63M
1 W Prestazione:
+7.00%
1M Prestazione:
+7.89%
6M Prestazione:
+91.13%
1 anno Prestazione:
+181.58%
Intervallo 1D:
$14.00
$15.01
Intervallo di 1 settimana:
$13.05
$15.87
Portata 52W:
$4.82
$15.87
Compass Pathways Plc Adr Stock (CMPS) Company Profile
Nome
Compass Pathways Plc Adr
Settore
Industria
Telefono
1-716-676-6461
Indirizzo
3RD FLOOR, 1 ASHLEY ROAD, CHESIRE
Compare CMPS vs HCA, THC, EHC, FMS, DVA
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CMPS
Compass Pathways Plc Adr
|
14.22 | 2.10B | 0 | -191.97M | -159.63M | -3.1575 |
HCA
Hca Healthcare Inc
|
421.21 | 91.33B | 76.39B | 7.81B | 7.93B | 29.08 |
THC
Tenet Healthcare Corp
|
263.46 | 21.67B | 21.46B | 2.65B | 3.35B | 19.23 |
EHC
Encompass Health Corp
|
121.04 | 11.99B | 6.07B | 793.80M | 464.40M | 5.9914 |
FMS
Fresenius Medical Care Ag Adr
|
22.23 | 11.88B | 22.44B | 1.35B | 2.03B | 1.9002 |
DVA
Davita Inc
|
181.33 | 11.68B | 13.84B | 1.10B | 1.49B | 10.42 |
Compass Pathways Plc Adr Stock (CMPS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Iniziato | B. Riley Securities | Buy |
| 2025-12-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-02-27 | Iniziato | Stifel | Buy |
| 2024-07-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-01 | Iniziato | Morgan Stanley | Overweight |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2022-11-21 | Ripresa | Berenberg | Buy |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2021-10-29 | Iniziato | Oppenheimer | Outperform |
| 2021-07-13 | Iniziato | Citigroup | Buy |
| 2021-06-28 | Iniziato | Maxim Group | Buy |
| 2021-05-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-01 | Iniziato | ROTH Capital | Buy |
| 2020-10-14 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-13 | Iniziato | Berenberg | Buy |
| 2020-10-13 | Iniziato | Canaccord Genuity | Buy |
| 2020-10-13 | Iniziato | Cowen | Outperform |
| 2020-10-13 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Compass Pathways Plc Adr Borsa (CMPS) Ultime notizie
Fluence to develop psilocybin therapy training for Compass - Investing.com
Compass Pathways Forecast: Breakout Could Target $22.51–$25.51 - FXEmpire
Compass Pathfinder Limited: Compass Pathways' New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year - finanznachrichten.de
Compass Pathways stock hits 52-week high at 15.4 USD - Investing.com
Compass Pathways stock shows durable results in depression trial - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
COMPASS Pathways (CMPS) Nears FDA Filing for COMP360 Following a Valuation Question - Sahm
Compass Pathways Target of Unusually High Options Trading (NASDAQ:CMPS) - MarketBeat
How COMPASS Pathways’ VA Psilocybin Trial (CMPS) Has Reframed Its Veteran Mental Health Ambitions - Sahm
Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances - Yahoo Finance
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
COMPASS Pathways plc (CMPS) stock price, news, quote and history - Yahoo Finance UK
HC Wainwright Cuts Earnings Estimates for Compass Pathways - MarketBeat
COMPASS Pathways (CMPS) Stock Looks Stretched Following Its 214% One Year Run - Sahm
COMPASS Pathways plc (5Y6.F) stock price, news, quote and history - Yahoo Finance Singapore
Renaissance Technologies LLC Reduces Stock Position in Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
Compass Pathways partners with VA on psilocybin trial for veterans - Investing.com
Compass Pathfinder Limited: Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin - FinanzNachrichten.de
Compass Pathways (NASDAQ:CMPS) Trading 9.8% HigherWhat's Next? - MarketBeat
Earnings call transcript: COMPASS Pathways advances q2 2026 launch plans as stock slips - Investing.com
COMPASS Pathways Reports Q2 2026 Financials and Updates on COMP360 Clinical Programs - Kalkine Media
Why is Compass Pathways stock rallying today? By Investing.com - Investing.com South Africa
Compass Pathways Q2 Earnings Call Highlights - Yahoo Finance
Seven Fleet Capital Management LP Buys 118,021 Shares of Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
200,000 Shares in Compass Pathways PLC Sponsored ADR $CMPS Acquired by Vivo Capital LLC - MarketBeat
Compass Pathways earnings on deck ahead of pivotal FDA filing - Investing.com
Eversept Partners LP Makes New $3.75 Million Investment in Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
Orbimed Advisors LLC Buys New Shares in Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
Affinity Asset Advisors LLC Purchases 908,483 Shares of Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
COMPASS Pathways plc (CMPS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cathie Wood Swaps Robinhood for SpaceX, Archer—Did ARK Pivot Back to Moonshot Innovation? - Sahm
Amova Asset Management Americas Inc. Has $2.03 Million Holdings in Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening - Sahm
Compass Pathways (NASDAQ:CMPS) Trading Down 5.5%Here's Why - MarketBeat
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer - Sahm
COMPASS Pathways (CMPS) Is Down 8.6% After Phase 3 Durability Data For COMP360 In TRD - Yahoo Finance
Compass Pathways study shows minimal interaction in psilocybin trials By Investing.com - Investing.com South Africa
Compass Pathways study shows minimal interaction in psilocybin trials - Investing.com
Should COMP360’s Durable Phase 3 Results and FDA Momentum Require Action From COMPASS Pathways (CMPS) Investors? - Sahm
Compass Pathways (NASDAQ:CMPS) Shares Gap UpTime to Buy? - MarketBeat
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up - Yahoo Finance
Compass Pathways stock reiterated Buy at H.C. Wainwright after trial data - Investing.com
Compass Pathways stock falls on Phase 3 trial data release By Investing.com - Investing.com South Africa
Compass Pathways stock falls on Phase 3 trial data release - Investing.com
Compass Pathways reports 6-month data from phase 3 TRD trial - Investing.com
Why is Compass Pathways stock gaining today? By Investing.com - Investing.com South Africa
Why is Compass Pathways stock gaining today? - Investing.com
Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026? - TradingView
AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026 - TradingView
Enterprise value to EBIT forward of COMPASS Pathways Plc Sponsored ADR – MUN:5Y6 - TradingView
Compass Pathways Plc Adr Azioni (CMPS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
0.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):